Given these challenges—the significant proportion of overlooked AFP-negative liver cancer cases, the dilemma of clinical triage and decision-making for AFP-negative focal hepatic lesions, and the inadequacy of existing prediction models to fully meet clinical needs—our objective is to establish a reliable predictive tool for discriminating and diagnosing AFP-negative focal hepatic lesions. This evidence concerns the gene AFP and liver cancer.